← Back to Search

Anti-metabolites

M3814 + Chemotherapy for Acute Myeloid Leukemia

Cincinnati, OH
Phase 1
Recruiting
Led By Brian A Jonas
Research Sponsored by National Cancer Institute (NCI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
- Refractory: no CR or CRi after one or more cycles of induction. Induction cycles include regimens with the intent to achieve remission and can include high intensity and/or low intensity regimens
Patients must be medically eligible to receive MEC, including acceptable pre-study cardiac function (left ventricular ejection fraction of >= 45%) and lifetime anthracycline exposure (=< 360 mg/m^2 daunorubicin equivalents)
Must not have
Patients must not have documented active central nervous system (CNS) involvement by leukemia. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events (AEs)
Patients must not have known significant cardiopulmonary disease defined as:
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug called M3814 combined with three chemotherapy drugs to treat patients with a difficult type of leukemia. The new drug blocks cancer cell growth, and the chemotherapy drugs kill or stop the cancer cells.

See full description
Who is the study for?
Adults (18+) with acute myeloid leukemia that's relapsed or hasn't responded to treatment, without severe allergies or conditions. They must have acceptable organ function and performance status, no active central nervous system involvement by leukemia, not be on certain medications affecting enzyme CYP3A4/5, and agree to use contraception.Check my eligibility
What is being tested?
The trial is testing the effectiveness of adding M3814 to standard chemotherapy drugs (mitoxantrone, etoposide phosphate, cytarabine) in patients with relapsed/refractory acute myeloid leukemia. It aims to find the best dose of M3814 and monitor its side effects when combined with these chemotherapies.See study design
What are the potential side effects?
Potential side effects include reactions related to cell growth inhibition by M3814 and typical chemotherapy effects like nausea, fatigue, hair loss except alopecia resolved to grade <=1 per NCI criteria. Organ inflammation and blood disorders may also occur.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer did not fully respond to initial treatment cycles aimed at remission.
 show original
Select...
My heart is strong enough for treatment, and I haven't had too much of a certain cancer drug.
 show original
Select...
All my side effects from previous cancer treatments, except hair loss, are mild or gone.
 show original
Select...
I am 18 years old or older.
 show original
Select...
I am mostly self-sufficient and can carry out daily activities.
 show original
Select...
I have been diagnosed with AML, not including the type known as APL.
 show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have leukemia affecting my brain.
 show original
Select...
I do not have serious heart or lung disease.
 show original
Select...
I haven't taken any experimental or new treatments for my leukemia in the last 14 days or less, except for treatments to control white blood cell counts.
 show original
Select...
I haven't taken strong medication affecting liver enzymes for at least 3 weeks.
 show original
Select...
I have never been treated with MEC.
 show original
Select...
I am not taking sorivudine or similar drugs.
 show original
Select...
I do not have severe heart failure.
 show original
Select...
I am not taking medications that affect my heart's electrical cycle.
 show original
Select...
I haven't had a live vaccine or an active infection in the last 30 days.
 show original
Select...
My heart's electrical cycle is longer than normal.
 show original
Select...
I have unstable chest pain.
 show original

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of adverse events
Secondary study objectives
Duration of CR/CRi
Event-free survival
Overall response rate
+2 more
Other study objectives
Effect of cytogenetic and molecular abnormalities
Pharmacodynamic effects of M3814 in combination with MEC
Rate of allogeneic hematopoietic cell transplantation (HCT)
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (peposertib, mitoxantrone, etoposide, cytarabine)Experimental Treatment8 Interventions
Patients receive peposertib PO BID on days 2-21, mitoxantrone IV over 15 minutes, etoposide IV over 60 minutes and cytarabine IV over 60 minutes on days 1-5 in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo ECHO and MUGA during baseline, and blood collection and bone marrow biopsy throughout the study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cytarabine
2016
Completed Phase 3
~4020
Multigated Acquisition Scan
2015
Completed Phase 3
~270
Biospecimen Collection
2004
Completed Phase 3
~1810
Bone Marrow Biopsy
2021
Completed Phase 3
~270
Etoposide Phosphate
2011
Completed Phase 2
~160
Mitoxantrone Hydrochloride
2016
Completed Phase 3
~650
Peposertib
2021
Completed Phase 1
~20

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Acute Myeloid Leukemia (AML) include chemotherapy, targeted therapy, and enzyme inhibitors. Chemotherapy drugs like cytarabine and daunorubicin work by killing rapidly dividing cells, which include cancer cells. Targeted therapies, such as FLT3 inhibitors, specifically target mutations in cancer cells, thereby reducing damage to normal cells. Enzyme inhibitors, like the investigational drug M3814, block specific enzymes necessary for cancer cell growth and survival. This is crucial for AML patients as it offers a more precise treatment approach, potentially reducing side effects and improving outcomes by directly targeting the molecular abnormalities driving the leukemia.
Progress in the problem of relapsed or refractory acute myeloid leukemia.Molecular targeting in acute myeloid leukemia.Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia.

Find a Location

Closest Location:University of Cincinnati Cancer Center-UC Medical Center· Cincinnati, OH

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor
14,028 Previous Clinical Trials
41,153,275 Total Patients Enrolled
Brian A JonasPrincipal InvestigatorCity of Hope Comprehensive Cancer Center LAO
3 Previous Clinical Trials
36 Total Patients Enrolled

Media Library

Cytarabine (Anti-metabolites) Clinical Trial Eligibility Overview. Trial Name: NCT03983824 — Phase 1
Acute Myeloid Leukemia Research Study Groups: Treatment (peposertib, mitoxantrone, etoposide, cytarabine)
Acute Myeloid Leukemia Clinical Trial 2023: Cytarabine Highlights & Side Effects. Trial Name: NCT03983824 — Phase 1
Cytarabine (Anti-metabolites) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03983824 — Phase 1
~3 spots leftby Jun 2025